FIGURE 1 - available via license: Creative Commons Attribution 4.0 International
Content may be subject to copyright.
Preferred Reporting Items for Systematic Review and MetaAnalyses (PRISMA) flow diagram of this meta-analysis.
Source publication
The aim of this study was to further explore the association between pretreatment prognostic nutritional index (PNI) and survival among advanced lung cancer patients who received the first-line immunotherapy based on current relevant studies. Several databases were searched up to July 17, 2023. Progression-free survival (PFS) and overall survival (...
Context in source publication
Similar publications
Background
To elucidate the treatment and surgery outcomes with or without perioperative therapies in Japanese patients with clinical stage III non‐small cell lung cancer (NSCLC) in real‐world settings.
Methods
We performed subset analyses of the SOLUTION study, a multicenter, noninterventional, observational study of Japanese patients diagnosed w...
This study explored the feasibility of adjuvant immunotherapy after NICT and surgery. A retrospective study was conducted on NSCLC patients who underwent NICT and surgery. Two patient groups were defined based on their adjuvant therapy after NICT and surgery: the Chemo group (chemotherapy alone) and the Immuno+Chemo group (chemotherapy combined wit...
Background
Lung cancer is the most common cancer in the world, and non-small cell lung cancer (NSCLC) constitutes about 80–85%. In this phase III trial, we evaluate the efficacy and safety of anti-programmed cell death-1 (PD-1) monoclonal antibody (SCT-I10A) plus docetaxel compared to docetaxel in patients with previously treated advanced squamous...
The association between depth of response (DpR) and treatment outcomes has been documented across various types of cancer. Immune checkpoint inhibitor (ICI)-based treatment is globally used as first-line treatment for non-small cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1) expression ≥ 50%. However, in this population, the signifi...
Background
Neoadjuvant immune checkpoint inhibitors(ICIs) combined with chemotherapy can improve non-small cell lung cancer(NSCLC) patients' pathological responses and show promising improvements in survival. Chronic obstructive pulmonary disease (COPD) is a systemic inflammatory disease, and its associated abnormal inflammatory response affects no...
Citations
... Alternatively, individuals with increased PD-L1 expression might not respond well to immunotherapy, and the practical use of these indicators could be constrained by the high costs of testing and the diverse nature of tumor samples. (18). ...
Platinum-based first-line chemotherapy for small lung cancers has been a mainstream therapy for the past several decades. However, its efficacy has been suboptimal, and the research is now focused on improving the treatment and prognosis of competitive nutrition and multidrug combination techniques. Small cell lung cancer (SCLC) is not only affected by smoking, age, sex and other external factors, but also the tumor micro-environment and the nutritional status of patients themselves are of great significance for the prevention and treatment of SCLC, a malignant tumor. According to past research, malnutrition is related to the intolerance to immunotherapy, decline in quality of life, psychological disturbances, and low survival rates and prognosis. Numerous studies have shown that a low Prognostic Nutritional Index (PNI) serves as an independent prognostic factor linked to reduced overall survival across various cancer types. Additionally, PNI has been associated with disease-free survival and progression-free survival in certain cancers, such as lung cancer (LC). Recent research has indicated that the PNI can serve as an independent predictor of both long-term outcomes and short-term complications in SCLC patients. However, a systematic consensus on this matter has yet to be established. This paper focuses on the role and influence of PNI in the immunotherapy of SCLC, and proposes the possibility of dietary therapy for SCLC patients under the guidance of PNI. Finally, the authors pointed out that PNI will become a new strategy for comprehensive immunotherapy of SCLC.
... The higher the PNI level, the better the prognosis of patients. Prior research indicates that PNI is linked to adult diseases, including malignant tumors, cardiovascular, autoimmune, and respiratory diseases (26)(27)(28)(29). Limited information exists on the role of PNI in predicting and diagnosing diseases in newborns. ...
Background
Bronchopulmonary dysplasia (BPD) is a severe chronic lung disease that primarily affects premature infants. BPD usually comes with delayed diagnosis, and the lung injury at the time of confirmed diagnosis is irreversible. The inflammatory response is a crucial pathogenic factor for BPD. The combination of prognostic nutritional index (PNI) and systemic inflammation response index (SIRI) is a comprehensive indicator that can reflect the balance between immune status and host inflammatory response. This study aimed to explore the predictive ability of SIRI and PNI for moderate-to-severe BPD (msBPD) in premature infants.
Methods
The research involved infants born before 32 weeks of gestational age (GA). The division of patients resulted in two groups: the control group with no or mild BPD and the msBPD group. Relevant data were collected to compare the differences regarding clinical data; SIRI and PNI were calculated within 24 hours after birth and at the time of diagnosis of BPD [at 36 weeks of postmenstrual age (PMA)]. The ability of SIRI and PNI to predict msBPD was evaluated by logistic regression analysis.
Results
A total of 491 infants were included in the study, with 435 infants in the control group and 56 infants in the msBPD group. The msBPD group exhibited lower PNI levels and higher SIRI levels compared to the control group. The area under the curve (AUC) value [95% confidence interval (CI): of SIRI and PNI were 0.599 (0.514–0.685) and 0.588 (0.504–0.672)], and the cut-off values were >1.927 and <34.105, respectively, within 24 hours after birth. The AUC value of SIRI and PNI were 0.602 (0.515–0.689) and 0.647 (0.569–0.725), and the cut-off values were >5.175 and <45.080, respectively, for the diagnosis of BPD at 36 weeks of PMA.
Conclusions
SIRI and PNI have a certain predictive and diagnostic values for managing msBPD in premature infants.
... p = 0.000), confirming the prognostic role of the PNI [26]. These data were also confirmed by a recent meta-analysis [27]. ...
Introduction: In recent years, several inflammation-related factors and nutritional parameters have been evaluated to develop prognostic scores as potential biomarkers in non-small-cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitors (ICIs). The aim of this study was to retrospectively investigate the prognostic role of the advanced lung cancer inflammation (ALI) index, lung immune prognostic index (LIPI), prognostic nutritional index (PNI) and systemic inflammation score (SIS) in metastatic NSCLC patients receiving ICI alone or in combination with chemotherapy. Methods and patients: We retrospectively included 191 patients with advanced NSCLC who received first-line ICI with or without chemotherapy from 2017 to 2024. The association between pretreatment ALI, LIPI, PNI, and SIS and overall survival (OS) was evaluated using the Kaplan–Meier method and Cox regression models. Results: After a median follow-up of 27.7 months, significantly longer OS was associated with an ALI score > 18 vs. ≤18 (18.0 vs. 7.3 months; p = 0.00111), LIPI score 0 vs. 1 and 2 [18.9 vs. 8.2 and 4.2 months; (p = 0.001)], PNI ≥ 45 vs. <45 (22.7 vs. 9.6 months; p = 0.002), and SIS score 0 vs. 1 and 2 (27.4 vs. 7.1 and 8.6 months, respectively; p < 0.001). The OS benefit was independent of treatment (ICI vs. ICI + chemotherapy). At multivariate analysis, pretreatment albumin was positively associated with OS, while ECOG PS 1 and liver metastases were negatively associated with OS. Conclusions: Inflammatory and nutritional biomarkers such as the ALI, LIPI, PNI, and SIS represent useful tools to prognosticate survival in metastatic lung cancer patients treated with ICI alone or in combination with chemotherapy as first-line.
